Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Maintenance Firm Aims For NASDAQ

This article was originally published in PharmAsia News

Executive Summary

Private health care management services firm iKang intends to list on NASDAQ within two years to become the first such enterprise out of China. iKang, which has attracted more than $25 million in investments from top venture capital firms - including Merrill Lynch, Shanghai Venture Capital, and ePlanet Ventures - is pursuing a "360-degree" health maintenance organization strategy. It has been adopting multiple approaches and concepts to cater to different consumer groups, with plans to aggressively expand its number of sites this year. Analysts see three stages in health care evolution: Treatment, prevention, and health management. While most developed nations have reached the third level, China's health care system still hovers between the first and second stages. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel